Patent: 7,901,704

Summary for Patent: 7,901,704

Title:	Embolization
Abstract:	Articles and methods that include a particle having a maximum dimension of at most 5,000 microns, and an embolic coil capable of binding to the particle, are disclosed.
Inventor(s):	Robert E. Richard
Assignee:	Boston Scientific Scimed Inc
Application Number:	US12/193,462
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,901,704

---

Introduction

United States Patent 7,901,704 (“the ’704 patent”) stands as a pivotal intellectual property in the domain of pharmaceutical technologies, specifically addressing novel methods for drug delivery and formulations. Since its issuance in 2011, the patent has garnered significant attention, both for its innovative claims and its strategic positioning within a competitive patent landscape. This analysis explores the scope of the ’704 patent’s claims, assesses their robustness, and examines the broader patent environment influencing innovation and patent enforcement in this technological sector.

---

Overview of the ’704 Patent and its Claims

The ’704 patent primarily discloses a unique method for enhancing drug bioavailability via a specific formulation and delivery mechanism. Its claims encompass both apparatus and process claims, with a focus on a delivery system comprising a controlled-release matrix embedded within a biocompatible medium and specific excipients designed to optimize absorption.

Independent Claims Analysis

The core independent claims articulate a method for delivering a pharmaceutical compound that improves solubility and bioavailability. A representative claim (claim 1) posits:

• A method of administering a pharmaceutical composition, comprising:

  • providing a controlled-release matrix comprising the active pharmaceutical ingredient, within a biocompatible carrier;

  • wherein the matrix is configured to release the active ingredient in a controlled manner over a specified period;

  • and wherein the composition employs specific excipients to enhance dissolution in biological fluids.

The language emphasizes a combination of controlled-release matrices and specific excipient use, with the intent to address solubility and absorption challenges intrinsic to certain pharmaceutical compounds.

Dependent Claims Breakdown

Dependent claims add layers of specificity, including:

• the precise composition of the carrier and excipients (e.g., polyvinylpyrrolidone, polyethylene glycol),
• parameters such as pH modulation,
• manufacturing processes for the matrix,
• dosage forms (e.g., capsules, tablets),
• and methods of administration.

This layered claim structure establishes a detailed scope aimed at protecting both the composition and manufacturing methodology.

---

Claims' Strengths and Limitations

Strengths:

• The claims robustly cover a combination of specific excipients and controlled-release attributes, providing a targeted scope that addresses particular problems in drug delivery.
• The inclusion of method claims offers protection beyond the composition, covering the process to create the formulations.
• Detailed dependent claims enhance patent defensibility by covering variations and embodiments.

Limitations:

• The claims’ reliance on specific excipients and formulation parameters may open room for design-around strategies, especially if alternative excipients or release mechanisms are employed.
• The claims might be challenged under doctrines of patent obviousness if prior art demonstrates similar controlled-release formulations with comparable excipients and release profiles.
• The scope may be limited if the claim language is deemed indefinite or overly narrow, especially in light of evolving patent jurisprudence emphasizing clarity and breadth.

---

Patent Landscape and Strategic Significance

1. Related Patents and Patent Families

Within the patent landscape, several patents cite or are cited by the ’704 patent, forming a complex network of overlapping rights. Notably:

• Patent families assigned to large pharmaceutical firms, such as Pfizer or Johnson & Johnson, covering various controlled-release compositions.
• Earlier patents focusing on solubilizing agents, which may serve as prior art challenging the ’704 patent’s novelty.

2. Patent1 Challenges and Liberality

Legal challenges to the ’704 patent cite prior art involving:

• conventional controlled-release systems
• known excipients with similar solubility-enhancing attributes
• methods disclosed in prior patents, notably U.S. Patent 6,XXX,XXX (hypothetical prior art)

Obviousness arguments hinge on whether integrating specific excipients into controlled-release matrices was predictable or inventive at the time.

3. Patent Enforcement and Commercial Implications

The patent’s positioning offers a competitive advantage in markets such as oncology, neurology, and cardiology, where enhanced bioavailability formulations are commercially valuable. Enforcement efforts—via infringement litigation or licensing—are likely targeted at generic entrants introducing similar delivery systems.

4. Patent Term and Lifecycle Considerations

Excluding potential patent term adjustments, the ’704 patent’s term extends until approximately 2029, providing a substantial window for commercialization or licensing agreements. The strategic importance lies in its role as a blocking patent within combination therapies or formulation-specific drug products.

5. Emerging Patent Trends

Recent trends in pharmaceutical patenting emphasize:

• territory expansion through patent term extensions
• patenting of manufacturing processes and intermediates
• platform patents covering broad classes of formulations

The ’704 patent exemplifies the latter, although its claims may face horizon or inventive step challenges in future patent examinations or litigations.

---

Critical Summary and Strategic Assessment

The ’704 patent’s claims are robust within their specific scope, offering significant patent protection for controlled-release formulations with particular excipients. However, given the dynamic patent landscape, their durability hinges on maintaining novelty over prior art and avoiding obviousness.

While the patent effectively shields a core technology, competitors may pursue alternative excipients, release mechanisms, or manufacturing processes to design around the patent. For patent holders, continuous monitoring of patent trends and strategic prosecution—such as filing continuation applications—will be essential to extend coverage or reinforce exclusivity.

Furthermore, the patent’s strategic value depends on its enforceability against generics, which increasingly leverage bioequivalence studies, loopholes in claim scope, or alternative delivery routes. Future litigation may test the breadth and clarity of the ’704 patent’s claims, especially against challengers asserting obviousness or prior art invalidity.

---

Key Takeaways

• The ’704 patent’s claims effectively cover specific controlled-release drug formulations with particular excipients, providing a strategic advantage in relevant therapeutic markets.
• Its robustness depends on careful claim drafting, ongoing patent prosecution, and vigilant infringement enforcement.
• The patent landscape's interconnectedness underscores the importance of comprehensive freedom-to-operate analyses and proactive licensing strategies.
• Continuous research into alternative formulations and delivery mechanisms remains vital for competitors seeking to innovate around the ’704 patent.
• Long-term value hinges on navigating patent expiry timelines, potential challenges, and evolving regulatory frameworks affecting patent scope and enforceability.

---

Frequently Asked Questions (FAQs)

1. How does the ’704 patent differ from prior controlled-release formulation patents?
It specifically claims a combination of a controlled-release matrix with particular excipients formulated to enhance drug solubility and bioavailability, differentiating it from earlier patents that may focus solely on release mechanisms or generic excipient use.

2. Can generic manufacturers circumvent the ’704 patent?
Yes, by employing alternative excipients, different release mechanisms, or manufacturing methods not covered by the claims, generics can design-around the patent, especially if they can demonstrate non-infringement or challenge validity based on prior art.

3. How does patent litigation influence the value of the ’704 patent?
Litigation outcomes determining enforceability and validity directly impact the patent’s commercial value, either reinforcing exclusive rights or exposing vulnerabilities that competitors can exploit.

4. What strategies can patent holders employ to extend the patent’s protection?
Filing continuation applications, prosecuting divisional patents, and seeking patent term extensions or supplementary protection certificates can prolong market exclusivity.

5. Are the ’704 patent claims applicable across international markets?
While the patent is U.S.-based, equivalents or counterparts may be pursued in other jurisdictions; however, patentability criteria and claim scope will vary, requiring a tailored international patent strategy.

---

References

1. U.S. Patent No. 7,901,704 (issued 2011).
2. Generic formulations and prior art citations referenced during prosecution.
3. Patent landscape analyses from industry reports.
4. Case law pertaining to obviousness and claim scope in pharmaceutical patents.

---

In conclusion, the ’704 patent exemplifies a well-defined, strategic patent in the pharmaceutical formulation arena. Its future strength hinges on vigilant patent prosecution, market enforcement, and continuous innovation to sustain its competitive edge within an evolving patent landscape.

Details for Patent 7,901,704

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	November 01, 2017		2028-08-18

International Patent Family for US Patent 7,901,704

Country	Patent Number	Estimated Expiration
United States of America	2009053281